Shared Resource Management

共享资源管理

• 批准号: 10332919
• 负责人: RICHARD D SCHULICK
• 金额: $ 273.69万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-04 至 2027-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10332919
• 关键词: Adopted; Advanced Malignant Neoplasm; Aging; Back; Basic Science; Bioinformatics; Biometry; Cancer Center; Cancer Center Support Grant; Capital; Cells; Charge; Chromium; Collaborations; Colorado; Consult; Cryoelectron Microscopy; Data; Data Science; Development; Education; Ensure; Equipment; Evaluation; Exposure to; Faculty; Feedback; Flow Cytometry; Funding; Future; Genomics; Goals; Human; Immune system; Immunologic Monitoring; Immunology; Information Networks; Institution; Investments; Journals; Laboratory Technicians; Magnetic Resonance Imaging; Malignant Neoplasms; Mass Spectrum Analysis; Medicine; Modeling; Nature; Organoids; Pathology; Peer Review; Performance; Postdoctoral Fellow; Process; Publications; Research; Research Infrastructure; Research Personnel; Resource Sharing; Resources; Running; Services; Strategic Planning; Structure; Students; Suggestion; System; Techniques; Technology; The University of Colorado Cancer Center; Training; Translations; Tumor Biology; Universities; Update; animal imaging; anticancer research; base; cancer cell; cost; drug development; drug discovery; empowered; functional genomics; high resolution imaging; high-throughput drug screening; improved; innovation; interest; liquid crystal polymer; mass spectrometer; member; mouse model; new technology; novel; population health; pre-clinical; single cell sequencing; structural biology; time use; transcriptome sequencing; tumor immunology

ABSTRACT Shared Resource (SR) Management is under the direction of the Associate Director for Basic Research, Ford (THI), and is structured to ensure that the University of Colorado Cancer Center (UCCC) invests in cutting edge technologies and research services that advance the research efforts of UCCC members. In the last cycle, the CCSG supported 10 SRs. Twelve SRs are presented in this renewal representing new SRs, added services and technologies, and restructured SRs that are aligned with UCCC members' current research and are focused on developing and innovating services and processes, and adopting new technologies to help drive members' research forward. The roster of SRs includes Animal Imaging, Biostatistics and Bioinformatics, Cell Technologies, Drug Discovery and Development, Flow Cytometry, Functional Genomics, Genomics, Human Immune Monitoring, Mass Spectrometry, Pathology, Population Health, and Structural Biology. In addition, a Pre-clinical Human Immune System Mouse Models SR is under development to support UCCC member research in tumor immunology and novel immunology-based therapies. To ensure that UCCC SRs serve members optimally, input and evaluation is solicited from users, internal and external advisory groups, and institutional stakeholders to inform decisions made by the UCCC Executive Committee (EC) on investments in, and changes to, UCCC SRs including the allocation of CCSG and institutional support, capital investments, development of new SRs, and sunsetting outdated or underperforming SRs. Over the past funding period, capital and operational investments totaling $26.9M have enabled the acquisition of cutting edge technologies such as multiplexed immunostaining (Vectra/MIBI), a NovaSeq 6000, a 10x Genomics Chromium to support single cell sequencing efforts, and a 9.4 Tesla MRI for high resolution imaging; upgrades of NMR systems, IncuCytes, IVIS and CT scanners; multiple mass spectrometers; addition of equipment to drive efficiencies (e.g. Sony MA900 self-run cell sorter; development of applications to support basic analyses of RNAseq data); replacement of aging equipment; and addition of services to drive member research forward (e.g. CryoEM for structural studies, organoid models for tumor biology studies, and high-throughput screening for drug discovery), while keeping all within reach of most funded investigators. Ninety-four percent (94% / n=247) of UCCC members have used the SRs over the funding period demonstrating the value of the SRs to members' research. Sixty percent (60%) of the UCCC users were peer-reviewed at the time of use. UCCC SRs contributed to 548 cancer-focused publications in the past cycle, many of which are high-profile as demonstrated by the fact that 21% have an impact factor (IF) ≥ 10 and that publications appear in journals such as Cell, Cancer Cell, and Nature Medicine. In short, UCCC SR Management is committed to ensuring each SR is providing essential, cutting edge equipment and services to UCCC members in their pursuit of advancing cancer research.

抽象的 共享资源（SR）管理处于基础研究副总监福特的指导下 （THI），并旨在确保科罗拉多大学癌症中心（UCCC）投资于最前沿 推进UCCC成员研究工作的技术和研究服务。在最后一个周期中， CCSG支持10个SR。在代表新SRS的此续订中介绍了十二个SRS，添加了服务 和技术，并恢复了与UCCC成员当前研究并列的SRS 开发和创新服务和流程，并采用新技术来帮助成员 研究前进。 SR的名册包括动物成像，生物统计学和生物信息学，细胞 技术，药物发现和发育，流式细胞术，功能基因组学，基因组学，人类 免疫监测，质谱，病理，人口健康和结构生物学。另外， 临床前的人免疫系统鼠标模型正在开发中，以支持UCCC成员 肿瘤免疫学和新型免疫学疗法的研究。确保UCCC SRS服务 成员最佳地，输入和评估是从用户，内部和外部咨询组以及 机构利益相关者向UCCC执行委员会（EC）做出的关于投资，， 以及UCCC SRS的更改，包括分配CCSG和机构支持，资本投资， 开发新的SR，以及过时或表现不佳的SR。在过去的资金期间，资本 以及总计2690万美元的运营投资，使得获得了尖端技术，例如 多路复用免疫染色（Vectra/Mibi），Novaseq 6000，10倍基因组铬，以支持单细胞 测序工作和9.4 Tesla MRI用于高分辨率成像； NMR系统，Incucytes，IVIS的升级 和CT扫描仪；多个质谱仪；增加设备提高效率（例如Sony MA900 自我运行的细胞分辨率；开发应用程序以支持RNASEQ数据的基本分析）；更换衰老 设备;并增加了推动会员研究前进的服务（例如结构研究的冷冻， 用于肿瘤生物学研究的器官模型，以及用于发现药物的高通量筛查），同时保持所有 在大多数资助的调查人员的范围内。 UCCC成员的94％（94％ / n = 247）使用了 在资金期间，SRS证明了SRS对成员研究的价值。 60％（60％） UCCC用户在使用时进行了同行评审。 UCCC SRS贡献了548个以癌症为中心的 过去周期中的出版物，其中许多是引人注目的，这证明了21％ 影响因子（如果）≥10，并且出版物出现在细胞，癌细胞和自然医学等期刊中。 简而言之，UCCC SR管理致力于确保每个SR提供必不可少的尖端 向UCCC成员提供的设备和服务，以追求癌症研究。